The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The
https://
ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
the contents by NLM or the National Institutes of Health.
Learn more:
PMC Disclaimer
Zhongguo Fei Ai Za Zhi.
2017 Nov 20; 20(11): 761–768.
Language:
Chinese
|
English
阿帕替尼用于一线治疗进展后晚期非鳞非小细胞肺癌的疗效和生存分析
Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment
,
,
,
,
,
and
*
王 学敏
300060 天津，天津医科大学肿瘤医院国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床研究中心，天津市肿瘤免疫与生物治疗重点实验室，生物治疗肿瘤科,
National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital; Key Laboratory of Cancer Prevention and Therapy; Tianjin Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy; Department of Biotherapy, Tianjin 300060, China
张 维红
300060 天津，天津医科大学肿瘤医院国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床研究中心，天津市肿瘤免疫与生物治疗重点实验室，生物治疗肿瘤科,
National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital; Key Laboratory of Cancer Prevention and Therapy; Tianjin Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy; Department of Biotherapy, Tianjin 300060, China
杜 伟娇
300060 天津，天津医科大学肿瘤医院国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床研究中心，天津市肿瘤免疫与生物治疗重点实验室，生物治疗肿瘤科,
National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital; Key Laboratory of Cancer Prevention and Therapy; Tianjin Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy; Department of Biotherapy, Tianjin 300060, China
张 新伟
300060 天津，天津医科大学肿瘤医院国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床研究中心，天津市肿瘤免疫与生物治疗重点实验室，生物治疗肿瘤科,
National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital; Key Laboratory of Cancer Prevention and Therapy; Tianjin Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy; Department of Biotherapy, Tianjin 300060, China
任 秀宝
300060 天津，天津医科大学肿瘤医院国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床研究中心，天津市肿瘤免疫与生物治疗重点实验室，生物治疗肿瘤科,
National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital; Key Laboratory of Cancer Prevention and Therapy; Tianjin Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy; Department of Biotherapy, Tianjin 300060, China
曹 水
300060 天津，天津医科大学肿瘤医院国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床研究中心，天津市肿瘤免疫与生物治疗重点实验室，生物治疗肿瘤科,
National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital; Key Laboratory of Cancer Prevention and Therapy; Tianjin Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy; Department of Biotherapy, Tianjin 300060, China
300060 天津，天津医科大学肿瘤医院国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床研究中心，天津市肿瘤免疫与生物治疗重点实验室，生物治疗肿瘤科,
National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital; Key Laboratory of Cancer Prevention and Therapy; Tianjin Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy; Department of Biotherapy, Tianjin 300060, China
